<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02934724</url>
  </required_header>
  <id_info>
    <org_study_id>2014/2333</org_study_id>
    <nct_id>NCT02934724</nct_id>
  </id_info>
  <brief_title>Impact of HPV Vaccine On The Prevalence Of HPV In Norway</brief_title>
  <official_title>Impact of HPV Vaccine On The Prevalence Of Human Papillomavirus In Mouth And Vagina In Norway</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of the study is to assess the effect of school-based Human Papillomavirus&#xD;
      (HPV) vaccination by comparing type-specific HPV prevalence between vaccinated and&#xD;
      non-vaccinated women born in 1997. Women born in 1997, residence to Norway in 2009 (the year&#xD;
      of vaccine initiation of the 1997-cohort) are invited to participate in the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This cohort is amongst the first that was offered HPV vaccine in an organized vaccination&#xD;
      programme globally. The women will be recruited through Facebook ads. The study will enable&#xD;
      us to measure differences in the prevalence of HPV types in vagina and the mouth between&#xD;
      vaccinated and non-vaccinated young women in Norway.&#xD;
&#xD;
      The womens vaccination status will be validated by linkage to the Norwegian Immunisation&#xD;
      Registry (SYSVAK) and their residence status will be validated through linkage to the&#xD;
      Norwegian Population Registry.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Vaginal and oral HPV-6, HPV-11, HPV-16 and HPV-18 prevalence</measure>
    <time_frame>Within 2 months after self-collection of specimens</time_frame>
    <description>The differences in HPV types prevalence among vaccinees and non-vaccinees. HPV types will be assessed individually and combined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Description of oral and vaginal overall genotype distribution among vaccinated and non-vaccination participants</measure>
    <time_frame>Within 2 months after self-collection of specimens</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">315</enrollment>
  <condition>Cervical Intraepithelial Neoplasia</condition>
  <condition>Cervical Cancer</condition>
  <condition>Oropharyngeal Cancer</condition>
  <arm_group>
    <arm_group_label>Vaccinated</arm_group_label>
    <description>Women born in 1997, resident to Norway in 2009, vaccinated by the quadrivalent HPV vaccine.&#xD;
Interventions:&#xD;
Self sample from vagina using Rover's Evalyn Brush&#xD;
Self sample from the oral cavity using COPAN's FloqSwab&#xD;
Questionnaire</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Un-vaccinated</arm_group_label>
    <description>Women born in 1997, resident to Norway in 2009, not vaccinated by the quadrivalent HPV vaccine&#xD;
Interventions:&#xD;
Self sample from vagina using Rover's Evalyn Brush&#xD;
Self sample from the oral cavity using COPAN's FloqSwab&#xD;
Questionnaire</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Self sample from vagina</intervention_name>
    <description>Self sample using The Rover's Evalyn Brush</description>
    <arm_group_label>Un-vaccinated</arm_group_label>
    <arm_group_label>Vaccinated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Self sample from the oral cavity</intervention_name>
    <description>Self sample using COPAN FloqSwab</description>
    <arm_group_label>Un-vaccinated</arm_group_label>
    <arm_group_label>Vaccinated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>Questionnaire about vaccination status and sexual behaviour</description>
    <arm_group_label>Un-vaccinated</arm_group_label>
    <arm_group_label>Vaccinated</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Self samples from vagina and the oral cavity&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women resident to Norway in 2009&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Born in 1997&#xD;
&#xD;
          -  Resident of Norway in 2009&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  Born before or after 1997&#xD;
&#xD;
          -  Non-resident of Norway in 2009&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Espen Enerly, Dr Scient</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giske Ursin, Dr.Med</last_name>
    <role>Study Director</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oslo University Hospital, Cancer Registry of Norway</name>
      <address>
        <city>Oslo</city>
        <zip>0379</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>PLOS ONE Staff. Correction: An observational study comparing HPV prevalence and type distribution between HPV-vaccinated and -unvaccinated girls after introduction of school-based HPV vaccination in Norway. PLoS One. 2019 Dec 12;14(12):e0226706. doi: 10.1371/journal.pone.0226706. eCollection 2019.</citation>
    <PMID>31830145</PMID>
  </reference>
  <results_reference>
    <citation>Enerly E, Flingtorp R, Christiansen IK, Campbell S, Hansen M, Myklebust TÅ, Weiderpass E, Nygård M. An observational study comparing HPV prevalence and type distribution between HPV-vaccinated and -unvaccinated girls after introduction of school-based HPV vaccination in Norway. PLoS One. 2019 Oct 10;14(10):e0223612. doi: 10.1371/journal.pone.0223612. eCollection 2019. Erratum in: PLoS One. 2019 Dec 12;14(12):e0226706.</citation>
    <PMID>31600341</PMID>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 13, 2016</study_first_submitted>
  <study_first_submitted_qc>October 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2016</study_first_posted>
  <last_update_submitted>December 10, 2020</last_update_submitted>
  <last_update_submitted_qc>December 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Espen Enerly</investigator_full_name>
    <investigator_title>Dr Scient</investigator_title>
  </responsible_party>
  <keyword>HPV vaccines</keyword>
  <keyword>HPV-6</keyword>
  <keyword>HPV-11</keyword>
  <keyword>HPV-16</keyword>
  <keyword>HPV-18</keyword>
  <keyword>Gardasil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

